Figure 1.
Classification systemof immunotherapies for pancreatic ductal adenocarcinoma (PDA). The tumor stroma impedes these therapies withmultiple immunosuppressive mechanisms described in the text. Stromal-directed treatments, such as focused ultrasound, have shown promising results in early clinical trials and may provide substantial clinical benefit as immuno-adjuvant therapy.